The transforming growth factor beta signaling pathway is strongly implicated in many common diseases considered to be multifactorial in etiology, including cancer, cardiovascular disease, asthma, fibrosis and inflammation. Human genetics has also shown a direct involvement in several birth defects, including Loeys- Dietz Syndrome, Marfan Syndrome, Camurati-Engelmann disease and Hereditary Hemorrhagic Telangiectasia, all caused by mutations in individual TGFbeta pathway genes. However, the action of TGFbeta is highly context-dependent, and depends on genetic interactions between gene variants. Thus the phenotypic spectrum of TGFB-associated diseases is highly variable. Utilizing mouse and human genetics, we have identified a genetic locus, TGFBM2, on distal mouse chromosome 1, human 1q41, that influences the phenotypic outcome of genetic reduction in TGFbeta signaling in the Tgfb1KO mice and in human Hereditary Haemorraghic Telangiectasia (HHT). We have mapped this genetic variation to a specific gene within TGFBM2 that is associated with appearance of arterio-venous malformations in Dutch HHT patients. The goals of the current project, are to replicate the human genetic association studies in an independent population of French Caucasian HHT families, and to more finely map the human region of genetic variation. We will validate a functional interaction between the TGFBM2 gene and the TGFB signaling pathway using in vitro siRNA assaysin mouse embryo fibroblasts derived from congenic mice that carry variants of TGFBM2. We will investigate molecular mechanisms of interaction between TGFBM2 and TGFB signaling using gene transfection studies and in vitro protein binding studies. We will validate the in vivo interaction between TGFBM2 and TGFB signaling utilizing existing and novel TGFBM2 and TGFB1 KO mice. Finally, we will examine the interaction of TGFBM2 with the BMP/ENG/ACVRL signaling pathway implicated in HHT, both in vitro, and by breeding TGFBM2 congenic and knock out mice to ENG KO mice. This information will increase understanding of genetic interactions that regulate TGFB biology in vivo, deepen understanding of predisposition to PAVM in particular, and to vascular disease in general.

Public Health Relevance

TGFB1 is a central player in many human diseases, and drug companies are now targeting this pathway for treatment of various diseases, including fibrosis and cancer, but its action depends on interactions with other genes. We have identified a gene that interacts with TGFB1 in mice and humans to alter vascular disease progression. Understanding how these molecules interact may ultimately help to design new or better drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM060514-08
Application #
8240045
Study Section
Genetics of Health and Disease Study Section (GHD)
Program Officer
Krasnewich, Donna M
Project Start
2001-02-01
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2014-03-31
Support Year
8
Fiscal Year
2012
Total Cost
$357,388
Indirect Cost
$126,069
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Kawasaki, Kyoko; Freimuth, Julia; Meyer, Dominique S et al. (2014) Genetic variants of Adam17 differentially regulate TGF? signaling to modify vascular pathology in mice and humans. Proc Natl Acad Sci U S A 111:7723-8
Lamouille, Samy; Connolly, Erin; Smyth, James W et al. (2012) TGF-ýý-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci 125:1259-73
Akhurst, Rosemary J (2010) Taking thalidomide out of rehab. Nat Med 16:370-2
Mao, Jian-Hua; Saunier, Elise F; de Koning, John P et al. (2006) Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. Proc Natl Acad Sci U S A 103:8125-30
Akhurst, Rosemary J (2006) Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr Opin Investig Drugs 7:513-21
Lacher, Markus D; Tiirikainen, Maarit I; Saunier, Elise F et al. (2006) Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res 66:1648-57
Poon, Ellen; Clermont, Frederic; Firpo, Meri T et al. (2006) TGFbeta inhibition of yolk-sac-like differentiation of human embryonic stem-cell-derived embryoid bodies illustrates differences between early mouse and human development. J Cell Sci 119:759-68
Harradine, Kelly A; Akhurst, Rosemary J (2006) Mutations of TGFbeta signaling molecules in human disease. Ann Med 38:403-14
Saunier, Elise F; Akhurst, Rosemary J (2006) TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 6:565-78
Tang, Yang; Lee, Kyeong Sook; Yang, HaiTao et al. (2005) Epistatic interactions between modifier genes confer strain-specific redundancy for Tgfb1 in developmental angiogenesis. Genomics 85:60-70

Showing the most recent 10 out of 13 publications